Disease management, clinical and preclinical research on OPMD
Interceptor Working Group Meeting and Workshop
Background: The INTERCEPTOR (Interception of oral cancer) COST Action addresses the challenge of unmet oral cancer prevention and bring new paradigm to disease management of oral potentially malignant disorders (OPMD). Relying on excellent translational research, patient care and education in Europe (EU) in the field of cancer medicine, INTERCEPTOR will develop future strategies of personalized OPMD preventive and care approaches. Pluridisciplinary expertise will involve and target a spectrum of keys actors to ensure a long-term success.
The event will allow working group (WG) 2 (Disease care management of patients with OPMD), 3 (EHealth tools dedicated to monitoring of patients with OPMD) and 4 (Preclinical and clinical research for the development of innovative preventive strategies) members to meet (day 1). Day 2 will be dedicated to a workshop on spatial biology, an important aspect emerging in the cancer field.
On April 29th three parallel WG sessions (WG 2, 3 and 4) will cover the following topics:
WG2
aims at standardizing clinical and pathological characteristics of OPMD (lead: Prof. Paolo Bossi; co-lead: Keith Hunter). An update on the setup of the OPMD board and the development of a check-list for histopathological criteria will be discussed. Activities are related to the following deliverables of INTERCEPTOR.
- Deliverable 7: setup an international OPMD international board
- Deliverable 8: definition of standardized protocols for diagnosis, treatment and monitoring of OPMD including histopathological criteria
WG3
aims at developing eHealth tools for monitoring patients with OPMD (lead: Prof Haly Holmes; co-lead: Daniela Elena Costea). An update on the progress of two ongoing reviews will be made: one scoping review on health-related quality of life (QoL) and one systematic review on patient-reported outcome tools (PROMs). Activities are related to the following deliverables of INTERCEPTOR.
- Deliverable 11: Overview of PROMs and checklists for monitoring early signs of oral cancer, psychological problems and lifestyles among OPMD patients
- Deliverable 16: White paper on the adaptation of the RE-AIM framework on implementation and upscaling of an eHealth application tailored to patients with OPMD
WG4
aims at fostering preclinical and clinical research (lead: Prof. Moshe Elkabets; co-lead: Prof. Paolo Bossi). An update by Bojan Poposki and Izge Sanliturk (YIs) on the ongoing review (Model systems to advance our understanding of OPMDs progression to oral cancers) will be made. A discussion on future plans to complete the following deliverables of INTERCEPTOR will be discussed.
- Deliverable 2: Definition of a clinical network, patient letter of information translated in different languages, case report forms for clinical/translational research
- Deliverable 9: Guidelines for research groups trained on generating OPMD models
On April 30th, INTERCEPTOR will host a workshop focusing on spatial biology and pathology.
Agenda DAY 1 – April 29th – WG Sessions (click to reveal)
|
|
Topic |
Who |
|
08:00-08:45 |
Venue and Registration |
|
|
08:45 |
Introduction and Welcome from WG leaders |
|
|
09:00 – 10:00 |
||
|
World Café |
Lead: Antonella Cardone / Communication officer Tristan Hanssen from CPE |
|
|
10:00 – 11:00 ** 30 min Coffee break ** 11:30 – 12:30 |
||
|
Parallel WG Sessions |
|
|
|
WG2 - Disease care management of patients with OPMD
|
Room A: Standardization of clinical assessment of OPMD Lead: Paolo Bossi · Essential requirements for diagnostic · Definition of the clinical prognostic factors of malignant transformation
Room B: Development of a check-list for histopathological assessment of OPMD Lead: Keith Hunter · Method · Proposed milestones |
|
|
WG3 - E-Health tools dedicated to monitoring of patients with OPMD |
Update on the scoping review on health-related quality of life (QoL) in patients with oral cancer Lead: Haly Holmes Update on the systematic review on patient-reported outcome tools (PROMs) in patients with oral cancer Lead: Daniela Elena Costea How to move forward to transfer current knowledge to patients with OPMD? |
|
|
WG4-Preclinical and clinical research for the development of innovative preventive strategies
|
Update by Bojan Poposki and Izge Sanliturk (YIs) on the ongoing review: Model systems to advance our understanding of OPMD progression to oral cancer Future plans: Preclinical research (Lead: Moshe Elkabets) · Guidelines for research groups trained on generating OPMD models? · Training schools? · Short-term scientific missions? Future plans: Clinical/Biomarker research (Lead: Pierre Saintigny or Zisis Kozlakidis or Marine Benaissa) · Definition of a clinical network · Patient letter of information translated in different languages · Case report forms for clinical/biomarker research |
|
|
12:30-14:00 |
||
|
**lunch break** |
||
|
14:00-15:00 |
||
|
Plenary session – All WGs
|
Summary and feedback of the WG discussions by 20’ each group, 1H |
|
|
15:00 – 15:30 |
||
|
** Coffee break ** |
||
|
15:30-17:30 |
||
|
Round Table – All WGs Discussion will involve WG2, WG3 and WG4. Synergy with WG1/registry (lead: Pr. Rui Amaral Mendes), WG5/biobanking and biomarkers (lead: Dr. Zisis Kozlakidis) and Cancer Patient Europe (lead: Antonella Cardone) |
Defining the journey of patients with OPMD from diagnosis to intervention and follow-up. |
|
|
Wrap-up
|
Action plan before OPMDay in Porto (PT) on June 6-7. |
|
Agenda DAY 2 – April 30th – Workshop on spatial biology and pathology (click to reveal)
|
|
Topic |
Who |
|
08:00 -08:45 |
Venue and Registration |
|
|
08:45 -09:00 |
Introduction and Welcome from WG leaders |
|
|
09:00 -09:45 |
Keynote 1 [Spatial immune landscape of tumors] - TBC |
Stéphanie Tissot, Centre Hospitalier Universitaire Vaudois, Lausanne - CH |
|
09:45-10:15 |
Quantitative analysis of H&E and fluorescence whole-slide images with QuPath |
Rammah Elnour Mustafa, University of Bergen - NO |
|
10:15-10:45 |
[Translational applications of Artificial intelligence in head and neck pathology] - TBC |
Carlo Caponio, Università degli studi di Foggia - IT |
|
10:45-11:15 |
**coffee break** |
|
|
11:15 -12:00 |
Keynote 2 [The use of spatial pathology in head and neck cancer] - TBC |
Christian Schürch, University Hospital and Comprehensive Cancer Center Tübingen - DE |
|
12:00-12:30 |
Large-scale multiplexed imaging data collection and analysis from tumor tissues within the IMI2 funded IMMUcan consortium |
Daniel Schulz, University of Zurich - CH |
|
12:30 -14:00 |
**lunch break** |
|
|
14:00 -14:45 |
Keynote 3 Spatially resolved imaging mass cytometry analysis of cancer-associated fibroblast phenotypes |
Bernd Bodenmiller, University of Zurich– CH (online) |
|
14:45-15:15 |
[Implementation of a statistical analysis pipeline for multiplex immunofluorescence and imaging mass cytometry] - TBC |
Lucas Michon, Cancer Research Center of Lyon and Centre Léon Bérard – FR |
|
15:15 - 15:30 |
**coffee break** |
|
|
15:30 -15:50 |
Akoya |
Company representative - TBD |
|
15:50 -16:10 |
10X Genomics |
Company representative - TBD |
|
16:10 -16:30 |
NanoString |
Company representative - TBD |
|
16:30:17:00 |
Wrap-up and closing remarks |
Susanna Chiocca and WG leaders |
Organizers
Interceptor Working Group Meeting and Workshop
Working Group 2
Disease care management of patients with OPMD
Pr. Paolo Bossi (Humanitas University - IT)
Pr. Keith Hunter (University of Sheffield - UK)
Working Group 3
E-Health tools dedicated to monitoring of patients with OPMD
Dr. Haly Holmes (University of the Western Cape- ZA)
Pr. Daniela Elena Costea (University of Bergen - NO)
Working Group 4
Preclinical and clinical research for the development of innovative preventive strategies
Pr. Moshe Elkabets (Ben-Gurion University of the Negev - IL)/ Pr Paolo
Local Organizer & MC Member
Dr Susanna Chiocca (IT)
Location & Venue
Interceptor Working Group Meeting and Workshop
Address
European Institute of Oncology (IEO) - Istituto Fondazione di Oncologia Molecolare (IFOM)
Campus Via Adamello 16, Milano
Local Organiser Contact in Milan: Dr Chiocca Susanna, susanna.chiocca@ieo.it
Itinerary
Department of Experimental Oncology
Find your way in Milan
General Information
Oral Cancer INTERCEPTION Workshop
Accomodation
Best Western Hotel Major - Viale Isonzo, 2, 20135 Milano MILAN
Join our Interceptor Working Group Meeting and Workshop!
Register Here
Project information
INTERCEPTOR aims to address the challenge of generating innovative and actionable pathways by engaging with the ‘critical practice’ dimensions of transformation.
A ‘critical practice’ approach explores transformation processes in practice across different dimensions which include research, policy, business, community and individual practices.
Action Contacts
Prof. Pierre Saintigny
Action Chair
+33(0)4 69 85 60 97
pierre.saintigny@lyon.unicancer.fr
Prof. Senada Koljenovic
Action Vice Chair
+31652090524
senada.koljenovic@uza.be
COST Contacts
Dr Rosella Magli
Science Officer
+3225333833
Rossella.Magli@cost.eu
Ms Carmencita Malimban
Administrative Officer
+3225333842
carmencita.malimban@cost.eu
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. www.cost.eu